Merck's Sales Continue to Slump; Vioxx Lawsuits Piling Up

Drug Industry Daily
KEYWORDS courts / Recall
A A

Merck’s sales revenue dipped 5 percent in the U.S. and 2 percent worldwide during the third quarter — a decline caused largely by the withdrawal of its painkiller Vioxx and slumping sales of its blockbuster cholesterol-lowering drug Zocor.

To View This Article:

Login

Subscribe To Drug Industry Daily